Accelerated Vascular Aging as a Paradigm for Hypertensive Vascular Disease: Prevention and Therapy

Canadian Journal of Cardiology

Volumn 32, Issue 5, 2016, Pages 680-686.e4

  Barton, Matthias ^a   Husmann, Marc ^b   Meyer, Matthias R ^c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

AGING; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL ASSESSMENT; DIABETES MELLITUS; DYSLIPIDEMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERTENSIVE NEPHROPATHY; INCIDENCE; KIDNEY DISEASE; MULTIINFARCT DEMENTIA; PREVALENCE; PROGERIA; REVIEW; RISK FACTOR; RISK REDUCTION; COMPLICATION; DIABETES COMPLICATIONS; NEPHRITIS; PATHOPHYSIOLOGY; RENOVASCULAR HYPERTENSION;

AGING; ANTIHYPERTENSIVE AGENTS; DEMENTIA, VASCULAR; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; HEART FAILURE; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; KIDNEY FAILURE, CHRONIC; MYOCARDIAL INFARCTION; NEPHRITIS; RISK FACTORS; VASCULAR STIFFNESS;

EID: 84964388680     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2016.02.062     Document Type: Review

References (158)

1. Barton M. Prevention and endothelial therapy of coronary artery disease. Curr Opin Pharmacol 2013, 13:226-241.
2. Osler W. The Principles and Practice of Medicine: Designed for the Use of Practitioners and Students of Medicine 1892, D. Appleton and Company, New York.
3. Osler W. Diseases of the circulatory system. Modern Medicine: Its Theory and Practice 1908, 431. Lea & Febiger, Philadelphia. W. Osler, T. McCrae (Eds.).
4. Bryan C.S. Osler-Inspirations From a Great Physician 1997, Oxford University Press, Oxford.
5. Watson J.D., Crick F.H. Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature 1953, 171:737-738.
6. Barton M. Aging and endothelin: determinants of disease. Life Sci 2014, 118:97-109.
7. Maddox B. The double helix and the 'wronged heroine'. Nature 2003, 421:407-408.
8. Barton M. Mechanisms and therapy of atherosclerosis and its clinical complications. Curr Opin Pharmacol 2013, 13:149-153.
9. Ross R. The pathogenesis of atherosclerosis. A perspective for the 1990s. Nature 1993, 362:801-809.
10. Ross R., Glomset J.A. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973, 180:1332-1339.
11. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001, 104:365-372.
12. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
13. Barton M. Aging and biomedicine 2005: where should we go from here?. Cardiovasc Res 2005, 66:187-189.
14. Harman D. The aging process: major risk factor for disease and death. Proc Natl Acad Sci U S A 1991, 88:5360-5363.
15. Fries J.F. Aging, natural death, and the compression of morbidity. N Engl J Med 1980, 303:130-135.
16. McGinnis J.M. Mortality trends and signs of health progress in the United States: improving understanding and action. JAMA 2015, 314:1699-1700.
17. Hajjar I., Goldstein F.C., Martin G.S., Quyyumi A.A. Roles of arterial stiffness and blood pressure in hypertension-associated cognitive decline in healthy adults. Hypertension 2016, 67:171-175.
18. Mannsverk J., Wilsgaard T., Mathiesen E.B., et al. Trends in modifiable risk factors are associated with declining incidence of hospitalized and non hospitalized acute coronary heart disease in a population. Circulation 2015, 133:74-81.
19. Kovacic J.C., Castellano J.M., Fuster V. Cardiovascular defense challenges at the basic, clinical, and population levels. Ann N Y Acad Sci 2012, 1254:1-6.
20. Barton M. Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis. Pflugers Arch 2010, 460:825-837.
21. Capell B.C., Collins F.S., Nabel E.G. Mechanisms of cardiovascular disease in accelerated aging syndromes. Circ Res 2007, 101:13-26.
22. Gerhard-Herman M., Smoot L.B., Wake N., et al. Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome. Hypertension 2012, 59:92-97.
23. Minamino T., Komuro I. Vascular aging: insights from studies on cellular senescence, stem cell aging, and progeroid syndromes. Nat Clin Pract Cardiovasc Med 2008, 5:637-648.
24. Silvera V.M., Gordon L.B., Orbach D.B., et al. Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson-Gilford progeria syndrome. AJNR Am J Neuroradiol 2013, 34:1091-1097.
25. Meyer M.R., Haas E., Barton M. Need for research on estrogen receptor function: importance for postmenopausal hormone therapy and atherosclerosis. Gend Med 2008, 5(suppl A):S19-S33.
26. Gerland P., Raftery A.E., Sevcikova H., et al. World population stabilization unlikely this century. Science 2014, 346:234-237.
27. Ng M., Fleming T., Robinson M., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014, 384:766-781.
28. Jono S., Shioi A., Ikari Y., Nishizawa Y. Vascular calcification in chronic kidney disease. J Bone Miner Metab 2006, 24:176-181.
29. Pant R., Marok R., Klein L.W. Pathophysiology of coronary vascular remodeling: relationship with traditional risk factors for coronary artery disease. Cardiol Rev 2014, 22:13-16.
30. Bramlage P., Wittchen H.U., Pittrow D., et al. Recognition and management of overweight and obesity in primary care in Germany. Int J Obes Relat Metab Disord 2004, 28:1299-1308.
31. Sakurai T., Iimuro S., Araki A., et al. Age-associated increase in abdominal obesity and insulin resistance, and usefulness of AHA/NHLBI definition of metabolic syndrome for predicting cardiovascular disease in Japanese elderly with type 2 diabetes mellitus. Gerontology 2010, 56:141-149.
32. Fontana L. Modulating human aging and age-associated diseases. Biochim Biophys Acta 2009, 1790:1133-1138.
33. Wyatt S.B., Winters K.P., Dubbert P.M. Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Am J Med Sci 2006, 331:166-174.
34. Barton M. Childhood obesity: a life-long health risk. Acta Pharmacol Sin 2012, 33:189-193.
35. Barton M., Furrer J. Cardiovascular consequences of the obesity pandemic: need for action. Expert Opin Investig Drugs 2003, 12:1757-1759.
36. Barton M., Meyer M.R. Postmenopausal hypertension: mechanisms and therapy. Hypertension 2009, 54:11-18.
37. Alosco M.L., Gunstad J., Xu X., et al. The impact of hypertension on cerebral perfusion and cortical thickness in older adults. J Am Soc Hypertens 2014, 8:561-570.
38. Cherubini A., Lowenthal D.T., Paran E., et al. Hypertension and cognitive function in the elderly. Am J Ther 2007, 14:533-554.
39. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease. Circulation 2003, 107:139-146.
40. Lakatta E.G., Cohen J.D., Fleg J.L., Frohlich E.D., Gradman A.H. Hypertension in the elderly: age- and disease-related complications and therapeutic implications. Cardiovasc Drugs Ther 1993, 7:643-653.
41. Oliver J., Rider O.J., Banerjee R., et al. Investigating a liver fat: arterial stiffening pathway in adult and childhood obesity. Arterioscler Thromb Vasc Biol 2016, 36:198-203.
42. Bittner V. Menopause and cardiovascular risk cause or consequence?. J Am Coll Cardiol 2006, 47:1984-1986.
43. Kok H.S., van Asselt K.M., van der Schouw Y.T., et al. Heart disease risk determines menopausal age rather than the reverse. J Am Coll Cardiol 2006, 47:1976-1983.
44. Lakatta E.G. So! What's aging? Is cardiovascular aging a disease?. J Mol Cell Cardiol 2015, 83:1-13.
45. Lane N. A unifying view of ageing and disease: the double-agent theory. J Theor Biol 2003, 225:531-540.
46. Puntmann V.O., Taylor P.C., Mayr M. Coupling vascular and myocardial inflammatory injury into a common phenotype of cardiovascular dysfunction: systemic inflammation and aging - a mini-review. Gerontology 2011, 57:295-303.
47. El Assar M., Angulo J., Rodriguez-Manas L. Oxidative stress and vascular inflammation in aging. Free Radic Biol Med 2013, 65:380-401.
48. Vlachopoulos C., Xaplanteris P., Aboyans V., et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis 2015, 241:507-532.
49. Peters M.J., Joehanes R., Pilling L.C., et al. The transcriptional landscape of age in human peripheral blood. Nat Commun 2015, 6:8570.
50. Wu X., Hakimi M., Wortmann M., et al. Gene expression of inflammasome components in peripheral blood mononuclear cells (PBMC) of vascular patients increases with age. Immun Ageing 2015, 12:15.
51. Frayling T.M., Timpson N.J., Weedon M.N., et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007, 316:889-894.
52. Despres J.P. Obesity and cardiovascular disease: weight loss is not the only target. Can J Cardiol 2015, 31:216-222.
53. Shulman G.I. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 2014, 371:1131-1141.
54. Klein S., Fontana L., Young V.L., et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004, 350:2549-2557.
55. Bauman A., McGill B., Powell K., et al. Tackling obesity: challenges ahead. Lancet 2015, 386:741-742.
56. Bramlage P., Pittrow D., Wittchen H.U., et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004, 17:904-910.
57. Husmann M., Jacomella V., Thalhammer C., Amann-Vesti B.R. Markers of arterial stiffness in peripheral arterial disease. Vasa 2015, 44:341-348.
58. Laurent S., Cockcroft J., Van Bortel L., et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588-2605.
59. Lam C.S., Xanthakis V., Sullivan L.M., et al. Aortic root remodeling over the adult life course: longitudinal data from the Framingham Heart Study. Circulation 2010, 122:884-890.
60. Amann K., Tyralla K., Gross M.L., et al. Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol 2003, 60(suppl 1):S13-S21.
61. Greenwald S.E. Ageing of the conduit arteries. J Pathol 2007, 211:157-172.
62. Briet M., Burns K.D. Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications. Clin Sci (Lond) 2012, 123:399-416.
63. London GM, Safar ME, Pannier B. Aortic aging in ESRD: structural, hemodynamic, and mortality implications [Epub ahead of print]. J Am Soc Nephrol 2015; pii: ASN.2015060617. Accessed April 8, 2016.
64. Cockcroft J., Mancia G. Vascular aging: shifting the paradigm of risk assessment and reduction in hypertension. J Hypertens 2012, 30:S1-S2.
65. Benetos A., Waeber B., Izzo J., et al. Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens 2002, 15:1101-1108.
66. McEniery C.M., Yasmin, Maki-Petaja K.M., et al. The impact of cardiovascular risk factors on aortic stiffness and wave reflections depends on age: the Anglo-Cardiff Collaborative Trial (ACCT III). Hypertension 2010, 56:591-597.
67. Childs B.G., Durik M., Baker D.J., van Deursen J.M. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med 2015, 21:1424-1435.
68. Barton M., Haudenschild C.C. Endothelium and atherogenesis: endothelial therapy revisited. J Cardiovasc Pharmacol 2001, 38(suppl 2):S23-S25.
69. Traupe T., Ortmann J., Munter K., Barton M. Endothelial therapy of atherosclerosis and its risk factors. Curr Vasc Pharmacol 2003, 1:111-121.
70. Ben-Shlomo Y., Spears M., Boustred C., et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 2014, 63:636-646.
71. Chen K., Zhou X., Sun Z. Haplodeficiency of klotho gene causes arterial stiffening via upregulation of scleraxis expression and induction of autophagy. Hypertension 2015, 66:1006-1013.
72. Rockey D.C., Bell P.D., Hill J.A. Fibrosis-a common pathway to organ injury and failure. N Engl J Med 2015, 372:1138-1149.
73. Kunz J. Can atherosclerosis regress? The role of the vascular extracellular matrix and the age-related changes of arteries. Gerontology 2002, 48:267-278.
74. Wang M., Monticone R.E., Lakatta E.G. Arterial aging: a journey into subclinical arterial disease. Curr Opin Nephrol Hypertens 2010, 19:201-207.
75. Libby P. Collagenases and cracks in the plaque. J Clin Invest 2013, 123:3201-3203.
76. Wang J., Uryga A.K., Reinhold J., et al. Vascular smooth muscle cell senescence promotes atherosclerosis and features of plaque vulnerability. Circulation 2015, 132:1909-1919.
77. McCaffrey T.A., Nicholson A.C., Szabo P.E., Weksler M.E., Weksler B.B. Aging and arteriosclerosis. The increased proliferation of arterial smooth muscle cells isolated from old rats is associated with increased platelet-derived growth factor-like activity. J Exp Med 1988, 167:163-174.
78. Virmani R., Avolio A.P., Mergner W.J., et al. Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. Comparison between occidental and Chinese communities. Am J Pathol 1991, 139:1119-1129.
79. Izzo J.L., Shykoff B.E. Arterial stiffness: clinical relevance, measurement, and treatment. Rev Cardiovasc Med 2001, 2:29-34. 37-40.
80. Cockcroft J.R., Wilkinson I.B., Webb D.J. The Trevor Howell Lecture. Age, arterial stiffness and the endothelium. Age Ageing 1997, 26(suppl 4):53-60.
81. McEniery C.M., Yasmin, Hall I.R., et al. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol 2005, 46:1753-1760.
82. Rogers W.J., Hu Y.L., Coast D., et al. Age-associated changes in regional aortic pulse wave velocity. J Am Coll Cardiol 2001, 38:1123-1129.
83. Wilkinson I.B., Franklin S.S., Cockcroft J.R. Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology. Hypertension 2004, 44:112-116.
84. Lee J.Y., Lee S.W., Lee W.S., et al. Prevalence and clinical implications of newly revealed, asymptomatic abnormal ankle-brachial index in patients with significant coronary artery disease. JACC Cardiovasc Interv 2013, 6:1303-1313.
85. Kim D.H., Kim J., Kim J.M., Lee A.Y. Increased brachial-ankle pulse wave velocity is independently associated with risk of cerebral ischemic small vessel disease in elderly hypertensive patients. Clin Neurol Neurosurg 2008, 110:599-604.
86. Barton M. Ageing as a determinant of renal and vascular disease: role of endothelial factors. Nephrol Dial Transplant 2005, 20:485-490.
87. Iannitti T., Palmieri B. Inflammation and genetics: an insight in the centenarian model. Hum Biol 2011, 83:531-559.
88. Wang M., Jiang L., Monticone R.E., Lakatta E.G. Proinflammation: the key to arterial aging. Trends Endocrinol Metab 2014, 25:72-79.
89. Fyhrquist F., Saijonmaa O., Strandberg T. The roles of senescence and telomere shortening in cardiovascular disease. Nat Rev Cardiol 2013, 10:274-283.
90. Armanios M., de Cabo R., Mannick J., et al. Translational strategies in aging and aging-related diseases. Nat Med 2015, 21:1395-1399.
91. Guzik T.J., Hoch N.E., Brown K.A., et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007, 204:2449-2460.
92. Fulop T., Le Page A., Fortin C., et al. Cellular signaling in the aging immune system. Curr Opin Immunol 2014, 29:105-111.
93. Holman R.L. Atherosclerosis-a pediatric nutrition problem?. Am J Clin Nutr 1961, 9:565-569.
94. Napoli C., Glass C.K., Witztum J.L., et al. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet 1999, 354:1234-1241.
95. McGill H.C., McMahan A., Gidding S.S. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation 2008, 117:1216-1227.
96. Wissler R.W., Strong J.P. Risk factors and progression of atherosclerosis in youth. PDAY Research Group. Pathological Determinants of Atherosclerosis in Youth. Am J Pathol 1998, 153:1023-1033.
97. McGill H.C., McMahan C.A., Zieske A.W., et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 2000, 20:1998-2004.
98. McGill H.C., McMahan C.A., Herderick E.E., et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002, 105:2712-2718.
99. McMahan A., Gidding S.S., Malcom G.T., et al. Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis. Pediatrics 2006, 118:1447-1455.
100. Gidding S.S., Rana J.S., Prendergast C., et al. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Risk Score in young adults predicts coronary artery and abdominal aorta calcium in middle age: the CARDIA study. Circulation 2016, 133:139-146.
101. Cardillo C., Campia U., Iantorno M., Panza J.A. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 2004, 43:36-40.
102. Safar M.E., Boudier H.S. Vascular development, pulse pressure, and the mechanisms of hypertension. Hypertension 2005, 46:205-209.
103. Versari D., Daghini E., Virdis A., Ghiadoni L., Taddei S. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol 2009, 157:527-536.
104. Virdis A., Bacca A., Colucci R., et al. Endothelial dysfunction in small arteries of essential hypertensive patients: role of cyclooxygenase-2 in oxidative stress generation. Hypertension 2013, 62:337-344.
105. Meyer M.R., Fredette N.C., Barton M., Prossnitz E.R. Regulation of vascular smooth muscle tone by adipose-derived contracting factor. PLoS One 2013, 8:e79245.
106. Traupe T., Lang M., Goettsch W., et al. Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens 2002, 20:2239-2245.
107. Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease - a thirthieth anniversary update. Acta Physiol (Oxf). [e-pub ahead of print]. doi:10.1111/apha.12646.
108. Barton M., Baretella O., Meyer M.R. Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction. Br J Pharmacol 2012, 165:591-602.
109. Feletou M., Huang Y., Vanhoutte P.M. Vasoconstrictor prostanoids. Pflugers Arch 2010, 459:941-950.
110. 2 formation (1). N Engl J Med 1988, 319:689-698.
111. 2 formation (2). N Engl J Med 1988, 319:761-767.
112. Pratico D., Tillmann C., Zhang Z.B., Li H., FitzGerald G.A. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A 2001, 98:3358-3363.
113. 2alpha elevates blood pressure and promotes atherosclerosis. Proc Natl Acad Sci U S A 2009, 106:7985-7990.
114. Heymes C., Habib A., Yang D., et al. Cyclo-oxygenase-1 and -2 contribution to endothelial dysfunction in ageing. Br J Pharmacol 2000, 131:804-810.
115. Bhattacharya I., Damjanovic M., Gut A., et al. Childhood obesity induced by a high-fat diet causes premature vascular aging involving endothelium-dependent mechanisms. Hypertension 2008, 52:e89.
116. Mozaffarian D. Achieving cardiovascular health: a bleak outlook or tremendous potential?. J Am Coll Cardiol 2011, 57:1697-1699.
117. Goettsch W., Lattmann T., Amann K., et al. Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo: implications for atherosclerosis. Biochem Biophys Res Commun 2001, 280:908-913.
118. Ortmann J., Amann K., Brandes R.P., et al. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 2004, 44:974-981.
119. Barton M. Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol 2008, 4:490-501.
120. Fogo A.B. Progression and potential regression of glomerulosclerosis. Kidney Int 2001, 59:804-819.
121. Benigni A., Corna D., Zoja C., et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 2009, 119:524-530.
122. Barton M., Tharaux P.L. Endothelin and the podocyte. Clin Kidney J 2012, 5:17-27.
123. Glouzon B.K., Barsalani R., Lagace J.C., Dionne I.J. Muscle mass and insulin sensitivity in postmenopausal women after 6-month exercise training. Climacteric 2015, 18:846-851.
124. Ferriolli E., Pessanha F.P., Marchesi J.C. Diabetes and exercise in the elderly. Med Sport Sci 2014, 60:122-129.
125. Viljoen A., Sinclair A.J. Diabetes and insulin resistance in older people. Med Clin North Am 2011, 95:615-629. xi-ii.
126. Shaw L.J., Narula J., Chandrashekhar Y. The never-ending story on coronary calcium: is it predictive, punitive, or protective?. J Am Coll Cardiol 2015, 65:1283-1285.
127. Gepner A.D., Young R., Delaney J.A., et al. Comparison of coronary artery calcium presence, carotid plaque presence, and carotid intima-media thickness for cardiovascular disease prediction in the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging 2015, 8. e002262.
128. Manson J.E., Allison M.A., Rossouw J.E., et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007, 356:2591-2602.
129. Puri R., Nicholls S.J., Shao M., et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol 2015, 65:1273-1282.
130. Emmanuele L., Ortmann J., Doerflinger T., Traupe T., Barton M. Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth. Biochem Biophys Res Commun 2003, 302:67-72.
131. Werner C., Furster T., Widmann T., et al. Physical exercise prevents cellular senescence in circulating leukocytes and in the vessel wall. Circulation 2009, 120:2438-2447.
132. Martin S.S., Sperling L.S., Blaha M.J., et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. J Am Coll Cardiol 2015, 65:1361-1368.
133. Nelson M.E., Rejeski W.J., Blair S.N., et al. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Circulation 2007, 116:1094-1105.
134. Llamas Velasco S., Contador I., Villarejo Galende A., Lora Pablos A., Bermejo-Pareja D. Physical activity as protective factor against dementia: a prospective population-based study (NEDICES). J Int Neuropsychol Soc 2015, 21:8617.
135. Kuehn B.M. The brain fights back: new approaches to mitigating cognitive decline. JAMA 2015, 314:2492-2494.
136. Loprinzi P.D. Application of the "Fat-but-Fit" paradigm in predicting 10-yr risk for an atherosclerotic cardiovascular disease (ASCVD) event using the pooled cohort risk equations among US adults. Int J Cardiol 2016, 202:297-299.
137. Kwon S., Janz K.F., Letuchy E.M., Burns T.L., Levy S.M. Active lifestyle in childhood and adolescence prevents obesity development in young adulthood. Obesity (Silver Spring) 2015, 23:2462-2469.
138. Lee I.M., Shiroma E.J., Lobelo F., et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 2012, 380:219-229.
139. Hallal P.C., Andersen L.B., Bull F.C., et al. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet 2012, 380:247-257.
140. Shah R.V., Murthy V.L., Colangelo L.A., et al. Association of fitness in young adulthood with survival and cardiovascular risk: the Coronary Artery Risk Development in Young Adults (CARDIA) study. JAMA Intern Med 2016, 176:87-95.
141. Halaweh H., Willen C., Grimby-Ekman A., Svantesson U. Physical activity and health related quality of life among community dwelling elderly. J Clin Med Res 2015, 7:845-852.
142. Shah A.M., Claggett B., Folsom A.R., et al. Ideal cardiovascular health during adult life and cardiovascular structure and function among the elderly. Circulation 2015, 132:1979-1989.
143. Perng W., Rifas-Shiman S.L., Kramer M.S., et al. Early weight gain, linear growth, and mid-childhood blood pressure. A prospective study in Project Viva. Hypertension 2016, 67:301-308.
144. Barton M., Meyer M.R., Haas E. Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits?. Arterioscler Thromb Vasc Biol 2007, 27:1669-1672.
145. Kohl H.W., Craig C.L., Lambert E.V., et al. The pandemic of physical inactivity: global action for public health. Lancet 2012, 380:294-305.
146. Hallal P.C., Lee I.M. Prescription of physical activity: an undervalued intervention. Lancet 2013, 381:356-357.
147. Huang C., Yu H., Koplan J.P. Can China diminish its burden of non-communicable diseases and injuries by promoting health in its policies, practices, and incentives?. Lancet 2014, 384:783-792.
148. Check Hayden E. Ageing pushed as a treatable condition. Regulators asked to consider innavative trial design. Nature 2015, 522:265-266.
149. Riera C.E., Dillin A. Can aging be 'drugged'?. Nat Med 2015, 21:1400-1405.
150. Kane G.C., Karon B.L., Mahoney D.W., et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 2011, 306:856-863.
151. Oktay A.A., Shah S.J. Current perspectives on systemic hypertension in heart failure with preserved ejection fraction. Curr Cardiol Rep 2014, 16:545.
152. Murea M., Freedman B.I. Essential hypertension and risk of nephropathy: a reappraisal. Curr Opin Nephrol Hypertens 2010, 19:235-241.
153. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
154. Ponticelli C., Sala G., Glassock R.J. Drug management in the elderly adult with chronic kidney disease: a review for the primary care physician. Mayo Clin Proc 2015, 90:633-645.
155. Wehling M. Multimorbidity and polypharmacy: which betablocker to use in relation to the pharmacokinetic profile and interaction potential. Arzneimittelforschung 2010, 60:57-63.
156. Zia A., Kamaruzzaman S.B., Tan M.P. Polypharmacy and falls in older people: balancing evidence-based medicine against falls risk. Postgrad Med 2015, 127:330-337.
157. Wright J.T., Williamson J.D., Whelton P.K., et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015, 373:2103-2116.
158. Touyz R.M., Dominiczak A.F. Successes of SPRINT, but still some hurdles to cross. Hypertension 2016, 67:268-269.